ANAB (AnaptysBio) Other Current Payables: $0.0 Mil (As of Mar. 2026)


ANAB AnaptysBio Inc ANAB
66 GF Score
Price $62.36
GF Value $60.78
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is AnaptysBio Other Current Payables?

AnaptysBio ANAB -1.75% 66 Other Current Payables is $0.0 Mil as of Mar. 2026. GuruFocus rates ANAB with a GF Score™ of 66/100 and a GF Value™ of $60.78 (Fairly Valued). The stock has 2 warning signs investors should review.

AnaptysBio's Other Current Payables for the quarter that ended in Mar. 2026 was $0.0 Mil.

AnaptysBio Other Current Payables Related Terms

AnaptysBio Other Current Payables Historical Data

* Premium members only.

The historical data trend for AnaptysBio's Other Current Payables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AnaptysBio Other Current Payables Chart

AnaptysBio Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Payables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

AnaptysBio Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Payables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
ANAB
66GF Score
AnaptysBio Inc ANAB
Other Current Payables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

AnaptysBio Other Current Payables Calculation

Other Current Payables is the payables owed and expected to be paid within one year or one operating cycle that not otherwise classified. It includes dividends payable and all other current payables.

Frequently Asked Questions Learn more about Other Current Payables →
What does a Other Current Payables of $0.0 Mil mean?
AnaptysBio (ANAB) has a Other Current Payables of $0.0 Mil as of Mar. 2026. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on AnaptysBio and its competitors.
Is AnaptysBio's Other Current Payables too high?
AnaptysBio's current Other Current Payables is $0.0 Mil. Overall, AnaptysBio has a GF Score™ of 66/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does AnaptysBio's Other Current Payables compare to ABSI and TSHA?
AnaptysBio's Other Current Payables of $0.0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Payables for a Biotechnology company?
A good Other Current Payables depends on the Biotechnology industry context. However, Other Current Payables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Payables mean?
A high Other Current Payables can signal that a stock is expensive relative to its fundamentals. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on AnaptysBio and its competitors. AnaptysBio's current Other Current Payables is $0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AnaptysBio stock overvalued right now?
Based on GuruFocus' analysis, AnaptysBio (ANAB) is currently considered Fairly Valued. The stock's GF Value™ is $60.78, compared to a current price of $62.36 — trading 2.6% above its estimated fair value. The current Other Current Payables is $0.0 Mil. AnaptysBio's overall GF Score™ is 66/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Payables calculated?
Other Current Payables is calculated from a company's financial statements. For AnaptysBio (ANAB), the current Other Current Payables is $0.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is AnaptysBio (ANAB) Overvalued in 2026?

Based on GuruFocus' analysis, AnaptysBio stock appears to be overvalued. The current stock price of $62.36 is trading 2.6% above its estimated GF Value™ of $60.78. GuruFocus considers AnaptysBio to be Fairly Valued.

Key valuation signals for ANAB:

  • Other Current Payables: $0.0 Mil
  • GF Value™: $60.78 vs. price of $62.36 (2.6% above fair value)
  • GF Score™: 66/100 with 2 warning signs

No single metric tells the full story. See the ANAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

AnaptysBio Business Description

Other Exchanges 0HFQ:UKAN6:Germany
Address 10770 Wateridge Circle, Suite 210, San Diego, CA, USA, 92121
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
66GF Score

Get the complete analysis for ANAB

Other Current Payables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$62.36
Price
$60.78
GF Value